Glaxosmithkline Share News (GSK)

Astrazeneca has a lot to prove, says The Share Centre

The Share Centre has rated Astrazeneca a 'hold' for medium-risk investors after fourth-quarter results from the drugmaker disappointed the market on Thursday, with the broker highlighting its preference for sector rival Glaxosmithkline (GSK). The company reported a 2% increase in revenues to $6.68bn

3rd UPDATE: AstraZeneca Profit Drops As It Bolsters Drug Portfolio

UK BROKER RATINGS: Investec Cuts Smiths Group To Sell From Hold

UK MORNING BRIEFING: BT Leads FTSE 100 On EE Deal Confirmation

2nd UPDATE: AstraZeneca Profit Drops As It Bolsters Drug Portfolio

AstraZeneca Profit Drops As It Moves To Further Bolster Drug Pipeline

AstraZeneca Profit Drops As It Moves To Further Bolster Drug Pipeline

MARKET COMMENT: Retreat In World Oil Price Flattens London Equities

UPDATE 2-Genmab data seen pointing to blockbuster drug

(Adds GlaxoSmithKline selling 7.9 pct stake in Genmab) By Teis Jensen COPENHAGEN, Feb 4 (Reuters) - Positive results from a trial by biotech company Genmab of its bone marrow cancer treatment could lead to the launch of a blockbuster drug earning $3.5 billion a year, analysts said on

London close: Stocks trim losses on Greek hopes, Chinese stimulus

A late rally helped the FTSE 100 to erase most of its losses on Wednesday as optimism surrounding Greece and stimulus measures in China lifted sentiment, though stocks still finished in the red after hitting a five-month high the previous day. London's Footsie ended the session down 0.2% at 6,860.02

REFILE-GSK sells stake in Denmark's Genmab

(Refiles to fix formatting error) LONDON, Feb 4 (Reuters) - GlaxoSmithKline has put its 7.9 percent stake in Danish biotech company Genmab up for sale to institutional investors, the British drugs giant said on Wednesday. "Since the announcement of the sale of GSK's marketed Oncology

GSK sells stake in Denmark's Genmab

LONDON, Feb 4 (Reuters) - GlaxoSmithKline has put its 7.9 percent stake in Danish biotech company Genmab up for sale to institutional investors, the British drugs giant said on Wednesday. "Since the announcement of the sale of GSK's marketed Oncology portfolio to Novartis, GSK has consider

GlaxoSmithKline To Sell Its 7.9% Stake In Denmark's Genmab Via Placing

UPDATE 2-GlaxoSmithKline sees better signs for lung drugs after tough 2014

* Q4 sales 6.19 billion stg vs consensus 6.20 billion stg * Q4 core EPS 27.3 pence versus consensus 25.9 pence * Sees signs of regaining respiratory market share * Novartis deal on track to close in first half of 2015 (Adds further CEO comment, analyst, updates shares) B

Sector movers: GSK leads defensive pharma stocks higher

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of